

## Special Issue

# Glycine-(and D-Serine)-Related Neurotransmission: Promising Therapeutic Targets with Still Unsolved Problems

### Message from the Guest Editor

The neurotransmitter glycine is involved in several physiological and pathological conditions in the Central Nervous System. This peculiar transmitter exhibits crucial inhibitory but also “excitatory” functions, the latter as a co-agonist of glutamate at the NMDA receptors. In this Special Issue, it is hoped that original research as well as review articles will help to increase and disseminate knowledge in the field. Finally, studies leading to advances in the basic knowledge of the above-mentioned biological systems are undoubtedly important and their submission is encouraged. Potential topics include (but are not limited to):

- Drugs interacting with glycine receptors or transporters and psychiatric disorders (schizophrenia, mood disorders, obsessive-compulsive disorder, addiction, cognitive disorders, etc.).
- D-serine and related pathological and pharmacological issues.
- Glycine/D-serine and pathological pain.
- Glycine/D-serine and neurodegenerative diseases, epilepsy, and startle syndromes, among others.
- Neurobiology of glycine-related neurotransmission, including interactions with other transmitters.

---

### Guest Editor

Dr. Luca Raiteri

Department of Pharmacy, Pharmacology and Toxicology Section,  
University of Genoa, Italy Viale Cembrano 4, 16148 Genoa, Italy

---

### Deadline for manuscript submissions

closed (30 June 2024)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/140383](https://mdpi.com/si/140383)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).